Compare
Lilly (Eli) vs Supernus Pharmaceuticals (LLY vs SUPN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Lilly (Eli) (LLY) returned +46.2% and Supernus Pharmaceuticals (SUPN) -18.4%; so far this year the figures are +26.0% and -27.1%.
Lilly (Eli) is the larger company by market value, about 838.0 times the size of Supernus Pharmaceuticals.
Revenue grew +45.5% at LLY and +26.9% at SUPN over the last year.
LLY yields 0.49%. SUPN yields 31.08%.
Data as of the latest close. Not investment advice.
Relative performance
| LLY | SUPN | |
|---|---|---|
| Price | $1,354.00 | $26.16 |
| 1-day | -0.79% | -2.17% |
| YTD | +25.99% | -27.09% |
| 1 year | +46.25% | -18.38% |
| 3 years | +144.20% | +34.22% |
| Market cap | $1.27T | $1.5B |
| P/E | 43.9 | — |
| P/S | 14.73 | 1.76 |
| P/B | 31.63 | 1.43 |
| Revenue growth | +45.50% | +26.90% |
| EPS growth | +50.70% | — |
| Gross margin % | 83.6 | 87.6 |
| Net margin % | 31.9 | -5.1 |
| ROE % | 68.5 | -4.1 |
| Debt / equity | 1.23 | 0.38 |
| FCF yield % | 2.4 | 5.7 |
| Dividend yield % | 0.49 | 31.08 |
| Beta | 0.29 | 0.66 |
| RSI (14) | 61.1 | 22.6 |
| Technical rating |